Tuffin Paula

Tuffin Paula, General Counsel and Chief Compliance Officer, has demonstrated a consistent pattern of selling activity in shares of Better Therapeutics, Inc. (BETR) over the past year, as reflected in SEC Form 4 filings. Out of 54 reported transactions, all have been sales or dispositions, totaling $1,889,136.82 in value. Notably, Paula has not engaged in any purchases of BETR shares during this period, underscoring a clear selling bias. Recent filings highlight this trend, with eight sales recorded in 2026 alone, including transactions on March 16 ($55,809), March 13 ($39,578.70), and February 17 ($235,529.01). Earlier in February, two significant sales occurred on February 12, totaling $229,879.84, further emphasizing the sustained divestment strategy. Paula’s transactions span a variety of codes, including "S" for sales and "F" for dispositions, with the latter often indicating the exercise of derivative securities such as stock options. For example, on December 11, 2025, four separate sales were reported, ranging from $4,910 to $243,815.90, collectively amounting to $371,510.44. This activity suggests a systematic approach to liquidating holdings, likely tied to the vesting of equity awards. While the filings do not provide insight into the rationale behind these transactions, the data reveals a consistent reduction in Paula’s stake in BETR over time. This pattern aligns with broader trends observed among corporate insiders, particularly those exercising and selling vested options as part of long-term financial planning.